Tesaro
| Tesaro
|
|
|---|---|
 |
|
| legal form | Incorporated |
| founding | 2010 |
| Seat | Waltham , MA USA |
| management | Lonnie Moulder, CEO ; Mary Lynne Hedley President |
| sales | $ 44.8 million (2016) |
| Branch | pharmacy |
| Website |
www.tesarobio.com www.tesarobio.de |
Tesaro Inc. (spelling TESARO) is an American biopharmaceutical company specializing in oncology , founded in 2010 and listed on the American technology exchange NASDAQ under the TSRO trademark. Tesaro is headquartered in Waltham , MA , USA . The European headquarters are in Zug, Switzerland, and the German branch is in Munich . At the end of 2018, the British GlaxoSmithKline (GSK) registered the takeover of Tesaro with the antitrust authorities.
The Tesaro company specializes in cancer. The development portfolio includes novel oncological products as well as concomitant medication to reduce side effects (e.g. nausea and vomiting).
Medication / pipeline
Tesaro's research focuses on various oncological areas: ovarian cancer (ovarian cancer), breast cancer (breast cancer) and various other solid tumors . Two drugs have already been approved in both the EU and the US. More are still in clinical development :
- Niraparib (trade name: Zejula ) is an orally active and potent PARP inhibitor that is being developed to treat ovarian and breast cancer. The approval for the treatment of ovarian cancer (ovarian cancer) has been granted in both the USA and the EU.
- Rolapitant (trade name: Varuby ) can be used to prevent delayed nausea and vomiting associated with highly or moderately emetogenic chemotherapy in adults. The active ingredient is to be combined with dexamethasone and a 5-HT3 receptor antagonist .
- Tesaro's Immuno- Oncology Platform: Antibodies to immune checkpoint receptors have recently shown promise in the treatment of certain solid tumors, including metastatic melanoma (skin cancer), renal cell carcinoma and non-small cell lung cancer .
Cooperations
In October 2017, Evotec and Tesaro announced that they had entered into a three-year strategic partnership for the development of immuno-oncological substances. Tesaro is also very interested in collaborations with other companies.
See also
Web links
Individual evidence
- ^ History , Company WebSite, accessed December 4, 2017
- ↑ a b Contact , Company WebSite, accessed December 4, 2017
- ↑ SENIOR LEADERSHIP , Company WebSite, accessed December 4, 2017
- ↑ TESARO Announces Fourth-Quarter 2016 Operating Results , PM TESARO from February 28, 2017, accessed on December 4, 2017
- ↑ TESARO, Inc. Real-Time Stock Quotes, WebSite NASDAQ, accessed December 4, 2017
- ↑ About Company WebSite, accessed December 4, 2017
- ↑ a b Pipeline Company WebSite, accessed December 4, 2017
- ↑ TESARO Announces Availability of Zejula ™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the US , PM TESARO of April 19, 2017, accessed December 4, 2017
- ↑ TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer , PM TESARO from November 20, 2017, accessed on December 4, 2017
- ↑ European public assessment report European public assessment report (EPAR) website of the EMA, accessed on December 4, 2017
- ↑ Varuby - EPAR Summary for the Public , EMA website, accessed December 4, 2017
- ↑ TESARO Announces US FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy , PM TESARO of October 25, 2017, accessed on December 4, 2017
- ↑ TESARO'S IMMUNO-ONCOLOGY PLATFORM , Company WebSite, accessed December 4, 2017
- ↑ Evotec and Tesaro enter strategic partnership to discover novel immuno-oncology agents ( Memento of the original dated December 4, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM Evotec, October 26, 2017, accessed December 4, 2017
- ↑ STRATEGIC "DRUG HUNTING" PARTNERSHIPS , Company WebSite, accessed December 4, 2017
